Landes Bioscience Journals: mAbs

Americas Antibody Congress: September 21-23, 2009, Washington D.C. USA
Susan E. Lacy, Christopher J. Bond, Dennis Benjamin, Hans-Peter Gerber, Dimiter Dimitrov and Janice M. Reichert
Pages 523 - 530

Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Patrick Chames and Daniel Baty
Pages 539 - 547
Antibody-maytansinoid conjugates for the treatment of myeloma
Robert J. Lutz and Kathleen R. Whiteman
Pages 548 - 551

Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism
Claire Dobson, Sarah Main, Philip Newton, Matthieu Chodorge, Karen Cadwallader, Robin Humphreys, Vivian Albert, Tristan J. Vaughan, Ralph R. Minter and Bryan M. Edwards
Pages 552 - 562
Charge-based analysis of antibodies with engineered cysteines: From multiple peaks to a single main peak

Open Access Article
Xiaoying (Nancy) Chen, Mary Nguyen, Fred Jacobson and Jun Ouyang
Pages 563 - 571
IgG2m4, an engineered antibody isotype with reduced Fc function
Zhiqiang An, Gail Forrest, Renee Moore, Michael Cukan, Peter Haytko, Lingyi Huang, Salvatore Vitelli, Jing Zhang Zhao, Ping Lu, Jin Hua, Christopher R. Gibson, Barrett R. Harvey, Donna Montgomery, Dennis Zaller, Fubao Wang and William Strohl
Pages 572 - 579

Predictive tools for stabilization of therapeutic proteins
Vladimir Voynov, Naresh Chennamsetty, Veysel Kayser, Bernhard Helk and Bernhardt L. Trout
Pages 580 - 582

Monoclonal antibodies and progressive multifocal leukoencephalopathy
Joseph R. Berger, Sidney A. Houff and Eugene O. Major
Pages 583 - 589
Sensitivity and resistance to EGF-R inhibitors: Approaches to enhance the efficacy of EGF-R antibodies
Matthias Peipp, Michael Dechant and Thomas Valerius
Pages 590 - 599
Guardians at the gate: Patent protection of therapeutic monoclonal antibodies through product life cycle management—Part 3
Kevin W. McCabe and Paul A. Calvo
Pages 600 - 603

Table of Contents